经皮免疫治疗的临床和动物研究进展  

Advances in clinical and animal studies for epicutaneous immunotherapy

作　　者：汪瑱 董威[1] 何家杨[1] 汪蔚[2] WANG Zhen;DONG Wei;HE Jia-yang;WANG Wei(Department of Pharmacy,The First Hospital of Jiaxing,First Affiliated Hospital of Jiaxing University,Jiaxing 314001,China;College of Materials and Textile Engineering,Jiaxing University,Jiaxing 314001,Zhejiang,China)

机构地区：[1]嘉兴市第一医院,嘉兴学院附属第一医院药学部,浙江嘉兴314001 [2]嘉兴学院材料与纺织工程学院,浙江嘉兴314001

出　　处：《中华临床免疫和变态反应杂志》2023年第6期569-578,共10页Chinese Journal of Allergy & Clinical Immunology

基　　金：浙江省基础公益研究计划(Q24H300009);嘉兴市科技计划项目(2023AY11012);浙江省“领雁”研发攻关计划项目(2023C01201);嘉兴市科技计划项目(2019AD32124)。

摘　　要：变应原特异性免疫治疗(AIT),即脱敏治疗,被认为是唯一可能改变变态反应疾病自然进程的对因疗法。传统制剂如安脱达与阿罗格采用皮下注射途径,称为皮下注射免疫治疗(SCIT)。舌下含服免疫治疗(SLIT)自1998年起获批应用,是SCIT的有效替代。此外,为提高患者依从性并安全有效地诱导免疫耐受,通过皮肤、口服以及淋巴结内注射等新途径的免疫治疗正在积极开展临床研究。本文重点阐述经皮免疫治疗(EPIT)的作用机制,临床和动物研究的最新进展,以及未来的发展方向,为EPIT的应用与推广提供重要的理论参考。Allergen-specific immunotherapy(AIT),or desensitization,is the only causative treatment for IgE-mediated allergic diseases.In clinics,traditional Alutard SQ and Novo-Helisen-Depot are administered subcutaneously,namely subcutaneous immunotherapy(SCIT).Sublingual immunotherapy(SLIT)is introduced in 1998 as an effective alternative for SCIT.Additionally,new routes of allergen administration such as epicutaneous,oral,and intralymphatic have lately been explored to satisfy the urgent demand for compliance,safety,and efficacy of treatments.This review summarizes the latest advances on mechanisms,clinical,and experimental studies of epicutaneous immunotherapy(EPIT).Also,we present an overview of future developing directions for EPIT,which offers an important basis for widespread application and promotion.

关 键 词：变态反应 经皮免疫治疗 角质层 朗格汉斯细胞 免疫佐剂 剥脱点阵激光 微针 

分 类 号：R593.1[医药卫生—内科学]